Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PPD Opens Vaccine Clinical Research Center In Taizhou: One Step Closer To Its Goal To Become China's Number One Service Provider

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - PPD has been touting the opening of its new Vaccines and Biologics Center of Excellence in Wayne, Pennsylvania, and now the company is pushing its vaccine expansion into China with the launch of a vaccine clinical research center in Taizhou China Medical City

You may also be interested in...



BIO Welcomes First Chinese Members: Shanghai Zhangjiang Park And Taizhou Medical City

SHANGHAI - BIO, the largest biotechnology organization with 1,200 members around the world, announced its first two members from China - Zhangjiang Hi-tech Park in Shanghai and China Medical City in Taizhou - during the group's annual convention in Chicago

Charles River-WuXi PharmaTech Deal Transforms China's CRO Landscape

Charles River's acquisition of WuXi PharmaTech, valued at $1.6 billion, is the largest merger so far in China's healthcare space and is likely to drastically change the CRO playing field in China

PPD Continues High-speed Expansion In Asia With Second Acquisition Of A China-based CRO This Quarter

BEIJING - As part of a rapid-fire expansion across Asia, the U.S.-headquartered PPD has outlined plans to purchase and merge with the Beijing-based contract research organization BioDuro

Related Content

UsernamePublicRestriction

Register

SC142496

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel